<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064985</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00086</org_study_id>
    <nct_id>NCT02064985</nct_id>
  </id_info>
  <brief_title>Ticagrelor China Pharmacokinetic/Pharmacodynamic Study</brief_title>
  <official_title>An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety
      study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese
      patients with stable coronary heart disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 36 patients will be randomized in order to ensure 10 patients per treatment are
      evaluable.Ticagrelor will be supplied as 45 mg, 60mg, and 90mg tablets. Following an 8 hour
      fast on single dose on Day 1 and Day 7; on multiple doses from Day 3 to Day 6. Prior to the
      first dose of study drug there will be a screening period of maximum of 19 days. Patients
      will report to the clinical pharmacology unit (CPU) on Day -2 and will remain confined there
      until completion of study procedures on Day 7, the patients will be discharged on Day 8. In
      addition, patients will return to the CPU for a follow up visit 2 to 5 days after the last
      dose. Each patients participation, including the screening period, will take approximately 33
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IPA on Day 1</measure>
    <time_frame>Baseline and at 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours,48 hours after dose intake on Day 1</time_frame>
    <description>The Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Primary variable: IPA (final extent) induced by 20µM ADP at each assessment point after single and multiple doses of ticagrelor measured by Light-Transmittance Aggregometry (LTA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPA on Day 7</measure>
    <time_frame>Baseline and at 0 hour, 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours after dose intake on Day 7</time_frame>
    <description>The inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Primary variable: IPA (final extent) induced by 20µM ADP at each assessment point after single and multiple doses of ticagrelor measured by Light-Transmittance Aggregometry (LTA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in PRU on Day 1</measure>
    <time_frame>Baseline and at 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours,48 hours after dose intake on Day 1</time_frame>
    <description>Percent Change from baseline in Platelet P2Y12 Reaction Units (PRU)(measured by VerifyNow) profiles of multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease on chronic low dose ASA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Ticagrelor on Day 7(1)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>Pharmacokinetics parameters of Ticagrelor on Day 7---Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Vital Signs Over Time---Blood Pressure</measure>
    <time_frame>Baseline, Day 1 to Day 7 and 2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (seated blood pressure [BP])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in PRU on Day 7</measure>
    <time_frame>Baseline and at 0 hour, 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours after dose intake on Day 7</time_frame>
    <description>Percent Change from baseline in Platelet P2Y12 Reaction Units (PRU)(measured by VerifyNow) profiles of multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease on chronic low dose ASA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIPA(Max)---Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>The time to peak IPA (TIPAmax) was estimated for ADP-induced final extent IPA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIPA(Max)---Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>The time to peak IPA (TIPAmax) was estimated for ADP-induced final extent IPA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC(Final Extent) on Day 1</measure>
    <time_frame>IPA was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
    <description>The area-under-the-effect curve (AUEC) was estimated for ADP-induced final extent IPA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC(Final Extent) on Day 7</measure>
    <time_frame>IPA was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>The area-under-the-effect curve (AUEC) was estimated for ADP-induced final extent IPA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Ticagrelor on Day 1(3)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
    <description>The pharmacokinetics parameter of ticagrelor on Day 1---tmax and t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Ticagrelor on Day 1(2)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
    <description>The pharmacokinetics parameters of Ticagrelor on Day 1---AUC(0-inf), AUC(0-12h) and AUC(0-t).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Ticagrelor on Day 7(2)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>The pharmacokinetics parameters of ticagrelor on Day 7---tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(1)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
    <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1---Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(3)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
    <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1: tmax and t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(1)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(4)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 7---tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite : Parent on Day 1--Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine Cmax ratio for the metabolite to that of the parent compound on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite : Parent on Day 7---Cmax</measure>
    <time_frame>Day 7</time_frame>
    <description>To determine Cmax ratio of metabolite to that of the parent compound on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Physical Examination, Summary of Abnormalities</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Hematology Laboratory Variables Over Time---hematocrit</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---All Allowed Concomitant Medications During Study Treatment</measure>
    <time_frame>All allowed concomitant medications during study treatment(up to 2-5 days after last dose), includes medications that began prior to randomization but were ongoing after randomization.</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Concomitant medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Causally Related Adverse Events by System Organ Class and Preferred Term</measure>
    <time_frame>Includes adverse events with an onset date on or after the date of first dose and up to and including the last study visit (up to 2-5 days after last dose).</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Assessment of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Ticagrelor on Day 1(1)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
    <description>The pharmacokinetics parameters of Ticagrelor on Day 1---Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Ticagrelor on Day 7(3)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>Pharmacokinetics parameters of Ticagrelor on Day 7---AUC(0-12h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Ticagrelor on Day 7(4)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>Pharmacokinetics parameters of Ticagrelor on Day 7---Accumulation ratio(ratio of Day 7 AUC(0-12h) to Day 1 AUC(0-12h))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Vital Signs Over Time---Height</measure>
    <time_frame>Baseline</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Height)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Vital Signs Over Time---Weight</measure>
    <time_frame>Baseline</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Vital Signs Over Time---Pulse Rate</measure>
    <time_frame>Baseline, Day 1 to Day 7 and 2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Pulse Rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(2)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
    <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1---AUC(0-12h), AUC(0-t) and AUC(0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(2)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---AUC(0-12h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(3)</measure>
    <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
    <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---Accumulation ratio(ratio of Day 7 AUC(0-12h) to Day 1 AUC(0-12h))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Hematology Laboratory Variables Over Time---Erythrocytes</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Erythrocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Hematology Laboratory Variables Over Time---Hemoglobin</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Hematology Laboratory Variables Over Time---Leukocytes</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Leukocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Hematology Laboratory Variables Over Time---Platelets</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Glucose</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Alanine Aminotransferase</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Alanine Aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Aspartate Aminotransferase</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Aspartate Aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Alkaline Phosphatase</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Alkaline Phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Creatinine</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Total Bilirubin</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Total Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Sodium</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Potassium</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Chloride</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Phosphate</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Phosphate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Albumin</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Protein</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Blood Urea Nitrogen</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Blood Urea Nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety---Clinical Chemistry Variables Over Time---Bicarbonate</measure>
    <time_frame>2 to 5 days after last dose</time_frame>
    <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite : Parent on Day 1--AUC(0-inf)</measure>
    <time_frame>Day 1</time_frame>
    <description>To determine AUC(0-inf) ratio for the metabolite to that of the parent compound on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters of Metabolite : Parent on Day 7---AUC(0-12h)</measure>
    <time_frame>Day 7</time_frame>
    <description>To determine AUC(0-12h) ratio of metabolite to that of the parent compound on Day 7.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Stable Coronary Heart Disease (CHD)</condition>
  <arm_group>
    <arm_group_label>Ticagrelor 45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 90mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhibition of Platelet Aggregation by &quot;Brilinta&quot;(Ticagrelor)</intervention_name>
    <description>To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).</description>
    <arm_group_label>Ticagrelor 45mg</arm_group_label>
    <arm_group_label>Ticagrelor 60mg</arm_group_label>
    <arm_group_label>Ticagrelor 90mg</arm_group_label>
    <other_name>&quot;Brilinta&quot;(Ticagrelor)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated written informed consent prior to any study specific
             procedures.

          2. Female or male Chinese (as defined by Chinese Regulatory) patients aged 18 years or
             older with suitable veins for cannulations or repeated venipunctures.

          3. Documented stable coronary heart disease (CHD) fulfilling all of the following, and
             taking 75-100 mg ASA daily treatment:

             Diagnosed stable angina pectoris per the guidance of Chinese Society of Cardiology
             published in 2007, patients with angina severity classified as I and II of Canadian
             Cardiovascular Society grading of angina pectoris.

          4. Female patients without pregnant potential

        Exclusion Criteria:

          1. Any indication for oral anticoagulant or dual antiplatelet treatment and chronic ASA
             with doses greater than 100 mg/day.

          2. Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow
             therapeutic index, or strong CYP3A inducers within 14 days preceding the first dose of
             study medication and during study treatment.

          3. Increased bleeding risk.

          4. Contraindication or other reason that ASA or ticagrelor should not be administered

          5. Patients that are scheduled for revascularization (eg, PCI, CABG) during the study
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haiyan Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 3rd Hospital of Peking University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <results_first_submitted>September 2, 2015</results_first_submitted>
  <results_first_submitted_qc>April 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 11, 2016</results_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was recruited on February 27th 2014 and the last patient's informed consent was obtained on Oct 24th 2014.</recruitment_details>
      <pre_assignment_details>22 participants did not meet includion/exclusion criteria. 2 participants withdrawed from study due to subject decision.1 participant withdrawed due to other reason. 36 participants were randomized and received study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor 45mg</title>
          <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor 60mg</title>
          <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
        </group>
        <group group_id="P3">
          <title>Ticagrelor 90mg</title>
          <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor 45mg</title>
          <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor 60mg</title>
          <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
        </group>
        <group group_id="B3">
          <title>Ticagrelor 90mg</title>
          <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="9.8"/>
                    <measurement group_id="B2" value="61.3" spread="7.0"/>
                    <measurement group_id="B3" value="57.9" spread="12.6"/>
                    <measurement group_id="B4" value="59.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>IPA on Day 1</title>
        <description>The Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Primary variable: IPA (final extent) induced by 20µM ADP at each assessment point after single and multiple doses of ticagrelor measured by Light-Transmittance Aggregometry (LTA).</description>
        <time_frame>Baseline and at 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours,48 hours after dose intake on Day 1</time_frame>
        <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>IPA on Day 1</title>
          <description>The Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Primary variable: IPA (final extent) induced by 20µM ADP at each assessment point after single and multiple doses of ticagrelor measured by Light-Transmittance Aggregometry (LTA).</description>
          <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
          <units>% IPA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.09" spread="25.956"/>
                    <measurement group_id="O2" value="25.87" spread="27.036"/>
                    <measurement group_id="O3" value="33.34" spread="31.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.20" spread="26.563"/>
                    <measurement group_id="O2" value="50.97" spread="32.747"/>
                    <measurement group_id="O3" value="61.64" spread="31.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.24" spread="21.160"/>
                    <measurement group_id="O2" value="84.10" spread="17.645"/>
                    <measurement group_id="O3" value="86.11" spread="22.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.44" spread="11.786"/>
                    <measurement group_id="O2" value="90.18" spread="9.232"/>
                    <measurement group_id="O3" value="96.24" spread="6.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.02" spread="8.965"/>
                    <measurement group_id="O2" value="94.32" spread="6.243"/>
                    <measurement group_id="O3" value="94.02" spread="6.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.25" spread="16.518"/>
                    <measurement group_id="O2" value="85.70" spread="15.237"/>
                    <measurement group_id="O3" value="90.70" spread="8.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.11" spread="34.165"/>
                    <measurement group_id="O2" value="49.38" spread="25.153"/>
                    <measurement group_id="O3" value="66.48" spread="21.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.09" spread="28.211"/>
                    <measurement group_id="O2" value="46.23" spread="17.352"/>
                    <measurement group_id="O3" value="55.64" spread="29.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.56" spread="22.956"/>
                    <measurement group_id="O2" value="27.25" spread="17.993"/>
                    <measurement group_id="O3" value="43.04" spread="25.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in PRU on Day 1</title>
        <description>Percent Change from baseline in Platelet P2Y12 Reaction Units (PRU)(measured by VerifyNow) profiles of multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease on chronic low dose ASA.</description>
        <time_frame>Baseline and at 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours,48 hours after dose intake on Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (e.g., non-compliance with study drug) will be included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in PRU on Day 1</title>
          <description>Percent Change from baseline in Platelet P2Y12 Reaction Units (PRU)(measured by VerifyNow) profiles of multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease on chronic low dose ASA.</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (e.g., non-compliance with study drug) will be included in the PD analysis set.</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.20" spread="13.712"/>
                    <measurement group_id="O2" value="-13.76" spread="22.786"/>
                    <measurement group_id="O3" value="-19.59" spread="23.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.00" spread="27.295"/>
                    <measurement group_id="O2" value="-35.25" spread="28.795"/>
                    <measurement group_id="O3" value="-67.70" spread="30.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.60" spread="16.492"/>
                    <measurement group_id="O2" value="-61.23" spread="23.304"/>
                    <measurement group_id="O3" value="-78.85" spread="18.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71.58" spread="22.220"/>
                    <measurement group_id="O2" value="-75.42" spread="15.315"/>
                    <measurement group_id="O3" value="-87.97" spread="11.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.27" spread="25.208"/>
                    <measurement group_id="O2" value="-67.98" spread="16.709"/>
                    <measurement group_id="O3" value="-81.08" spread="11.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.93" spread="23.584"/>
                    <measurement group_id="O2" value="-47.15" spread="20.310"/>
                    <measurement group_id="O3" value="-73.47" spread="13.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.94" spread="20.706"/>
                    <measurement group_id="O2" value="-28.34" spread="19.865"/>
                    <measurement group_id="O3" value="-54.61" spread="19.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.57" spread="17.655"/>
                    <measurement group_id="O2" value="-1.91" spread="18.120"/>
                    <measurement group_id="O3" value="-22.59" spread="24.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.19" spread="23.331"/>
                    <measurement group_id="O2" value="-0.57" spread="13.070"/>
                    <measurement group_id="O3" value="-16.38" spread="18.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Ticagrelor on Day 7(1)</title>
        <description>Pharmacokinetics parameters of Ticagrelor on Day 7---Cmax</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Ticagrelor on Day 7(1)</title>
          <description>Pharmacokinetics parameters of Ticagrelor on Day 7---Cmax</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616.0" spread="37.09"/>
                    <measurement group_id="O2" value="689.4" spread="33.64"/>
                    <measurement group_id="O3" value="1273" spread="43.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Vital Signs Over Time---Blood Pressure</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (seated blood pressure [BP])</description>
        <time_frame>Baseline, Day 1 to Day 7 and 2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Vital Signs Over Time---Blood Pressure</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (seated blood pressure [BP])</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic Blood Pressure- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" spread="7.6"/>
                    <measurement group_id="O2" value="77.1" spread="9.7"/>
                    <measurement group_id="O3" value="74.8" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure- Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" spread="9.0"/>
                    <measurement group_id="O2" value="78.2" spread="9.6"/>
                    <measurement group_id="O3" value="74.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure-Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" spread="9.3"/>
                    <measurement group_id="O2" value="74.8" spread="7.5"/>
                    <measurement group_id="O3" value="74.2" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure-Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="11.0"/>
                    <measurement group_id="O2" value="75.2" spread="7.5"/>
                    <measurement group_id="O3" value="74.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure-Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" spread="11.4"/>
                    <measurement group_id="O2" value="78.2" spread="8.7"/>
                    <measurement group_id="O3" value="73.3" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure-Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" spread="10.3"/>
                    <measurement group_id="O2" value="75.2" spread="5.6"/>
                    <measurement group_id="O3" value="74.7" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure-Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" spread="8.7"/>
                    <measurement group_id="O2" value="77.4" spread="4.8"/>
                    <measurement group_id="O3" value="73.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure-Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" spread="7.7"/>
                    <measurement group_id="O2" value="75.6" spread="6.7"/>
                    <measurement group_id="O3" value="74.0" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure-2-5 days after last Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" spread="6.8"/>
                    <measurement group_id="O2" value="74.7" spread="6.7"/>
                    <measurement group_id="O3" value="71.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure (mmHg)-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.6" spread="14.6"/>
                    <measurement group_id="O2" value="129.2" spread="11.6"/>
                    <measurement group_id="O3" value="132.1" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.2" spread="12.0"/>
                    <measurement group_id="O2" value="135.7" spread="19.2"/>
                    <measurement group_id="O3" value="127.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure-Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.3" spread="15.0"/>
                    <measurement group_id="O2" value="131.4" spread="20.0"/>
                    <measurement group_id="O3" value="123.1" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure-Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.3" spread="11.0"/>
                    <measurement group_id="O2" value="130.1" spread="18.8"/>
                    <measurement group_id="O3" value="123.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure-Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.3" spread="12.8"/>
                    <measurement group_id="O2" value="132.8" spread="15.3"/>
                    <measurement group_id="O3" value="126.1" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure-Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.4" spread="11.0"/>
                    <measurement group_id="O2" value="131.3" spread="18.6"/>
                    <measurement group_id="O3" value="125.1" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure-Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.8" spread="14.0"/>
                    <measurement group_id="O2" value="133.5" spread="19.5"/>
                    <measurement group_id="O3" value="119.1" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure-Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.9" spread="11.8"/>
                    <measurement group_id="O2" value="129.4" spread="22.7"/>
                    <measurement group_id="O3" value="122.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure-2-5 days after last Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.0" spread="16.0"/>
                    <measurement group_id="O2" value="132.3" spread="17.3"/>
                    <measurement group_id="O3" value="124.7" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IPA on Day 7</title>
        <description>The inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Primary variable: IPA (final extent) induced by 20µM ADP at each assessment point after single and multiple doses of ticagrelor measured by Light-Transmittance Aggregometry (LTA).</description>
        <time_frame>Baseline and at 0 hour, 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours after dose intake on Day 7</time_frame>
        <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>IPA on Day 7</title>
          <description>The inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Primary variable: IPA (final extent) induced by 20µM ADP at each assessment point after single and multiple doses of ticagrelor measured by Light-Transmittance Aggregometry (LTA).</description>
          <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
          <units>% IPA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.69" spread="20.547"/>
                    <measurement group_id="O2" value="89.26" spread="7.857"/>
                    <measurement group_id="O3" value="95.10" spread="6.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.70" spread="15.998"/>
                    <measurement group_id="O2" value="89.96" spread="7.985"/>
                    <measurement group_id="O3" value="96.90" spread="3.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.82" spread="15.639"/>
                    <measurement group_id="O2" value="93.28" spread="7.589"/>
                    <measurement group_id="O3" value="96.47" spread="4.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.30" spread="17.325"/>
                    <measurement group_id="O2" value="94.62" spread="3.787"/>
                    <measurement group_id="O3" value="98.29" spread="3.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.00" spread="13.212"/>
                    <measurement group_id="O2" value="97.01" spread="2.258"/>
                    <measurement group_id="O3" value="98.86" spread="2.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.13" spread="14.344"/>
                    <measurement group_id="O2" value="92.94" spread="17.847"/>
                    <measurement group_id="O3" value="98.87" spread="2.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.55" spread="16.918"/>
                    <measurement group_id="O2" value="92.01" spread="7.316"/>
                    <measurement group_id="O3" value="96.81" spread="4.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in PRU on Day 7</title>
        <description>Percent Change from baseline in Platelet P2Y12 Reaction Units (PRU)(measured by VerifyNow) profiles of multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease on chronic low dose ASA.</description>
        <time_frame>Baseline and at 0 hour, 0.5 hour, 1 hour, 2 hours, 3 hours, 6 hours, 12 hours after dose intake on Day 7</time_frame>
        <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in PRU on Day 7</title>
          <description>Percent Change from baseline in Platelet P2Y12 Reaction Units (PRU)(measured by VerifyNow) profiles of multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease on chronic low dose ASA.</description>
          <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.90" spread="17.632"/>
                    <measurement group_id="O2" value="-80.07" spread="14.691"/>
                    <measurement group_id="O3" value="-89.33" spread="8.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.70" spread="17.742"/>
                    <measurement group_id="O2" value="-78.40" spread="18.103"/>
                    <measurement group_id="O3" value="-94.10" spread="6.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.23" spread="17.304"/>
                    <measurement group_id="O2" value="-85.00" spread="12.020"/>
                    <measurement group_id="O3" value="-88.81" spread="13.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.98" spread="18.434"/>
                    <measurement group_id="O2" value="-86.96" spread="12.868"/>
                    <measurement group_id="O3" value="-92.13" spread="9.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.71" spread="20.067"/>
                    <measurement group_id="O2" value="-75.07" spread="14.806"/>
                    <measurement group_id="O3" value="-91.48" spread="7.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours after dose intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.63" spread="23.767"/>
                    <measurement group_id="O2" value="-69.03" spread="19.867"/>
                    <measurement group_id="O3" value="-88.60" spread="8.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TIPA(Max)---Day 1</title>
        <description>The time to peak IPA (TIPAmax) was estimated for ADP-induced final extent IPA.</description>
        <time_frame>Day 1</time_frame>
        <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>TIPA(Max)---Day 1</title>
          <description>The time to peak IPA (TIPAmax) was estimated for ADP-induced final extent IPA.</description>
          <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="17.632" lower_limit="2.5" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.5" spread="14.691" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.5" spread="8.923" lower_limit="2.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TIPA(Max)---Day 7</title>
        <description>The time to peak IPA (TIPAmax) was estimated for ADP-induced final extent IPA.</description>
        <time_frame>Day 7</time_frame>
        <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>TIPA(Max)---Day 7</title>
          <description>The time to peak IPA (TIPAmax) was estimated for ADP-induced final extent IPA.</description>
          <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="17.632" lower_limit="1.0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="6.0" spread="14.691" lower_limit="1.8" upper_limit="6.0"/>
                    <measurement group_id="O3" value="1.3" spread="8.923" lower_limit="0.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUEC(Final Extent) on Day 1</title>
        <description>The area-under-the-effect curve (AUEC) was estimated for ADP-induced final extent IPA.</description>
        <time_frame>IPA was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
        <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>AUEC(Final Extent) on Day 1</title>
          <description>The area-under-the-effect curve (AUEC) was estimated for ADP-induced final extent IPA.</description>
          <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
          <units>%*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2474.4" spread="949.3" lower_limit="1.0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2819.4" spread="707.17" lower_limit="1.8" upper_limit="6.0"/>
                    <measurement group_id="O3" value="3301.0" spread="788.72" lower_limit="0.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUEC(Final Extent) on Day 7</title>
        <description>The area-under-the-effect curve (AUEC) was estimated for ADP-induced final extent IPA.</description>
        <time_frame>IPA was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>AUEC(Final Extent) on Day 7</title>
          <description>The area-under-the-effect curve (AUEC) was estimated for ADP-induced final extent IPA.</description>
          <population>All randomly assigned patients who received at least 1 dose of ticagrelor with post-dose PD measurements available and no protocol deviation considered to significantly affect the integrity of PD results (eg, non-compliance with study drug).</population>
          <units>%*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1069.9" spread="176.89" lower_limit="1.0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="1120.1" spread="108.44" lower_limit="1.8" upper_limit="6.0"/>
                    <measurement group_id="O3" value="1176.9" spread="33.03" lower_limit="0.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Ticagrelor on Day 1(3)</title>
        <description>The pharmacokinetics parameter of ticagrelor on Day 1---tmax and t1/2</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Ticagrelor on Day 1(3)</title>
          <description>The pharmacokinetics parameter of ticagrelor on Day 1---tmax and t1/2</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="38.02" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="3.00" spread="34.14" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.00" spread="37.39" lower_limit="1.00" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t½</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.07" spread="51.42" lower_limit="9.21" upper_limit="15.9"/>
                    <measurement group_id="O2" value="9.008" spread="32.46" lower_limit="7.94" upper_limit="12.5"/>
                    <measurement group_id="O3" value="9.802" spread="53.84" lower_limit="7.81" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Ticagrelor on Day 1(2)</title>
        <description>The pharmacokinetics parameters of Ticagrelor on Day 1---AUC(0-inf), AUC(0-12h) and AUC(0-t).</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Ticagrelor on Day 1(2)</title>
          <description>The pharmacokinetics parameters of Ticagrelor on Day 1---AUC(0-inf), AUC(0-12h) and AUC(0-t).</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3220" spread="51.42"/>
                    <measurement group_id="O2" value="3633" spread="32.46"/>
                    <measurement group_id="O3" value="6234" spread="53.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3102" spread="49.79"/>
                    <measurement group_id="O2" value="3533" spread="31.68"/>
                    <measurement group_id="O3" value="6017" spread="51.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2114" spread="41.97"/>
                    <measurement group_id="O2" value="2313" spread="30.10"/>
                    <measurement group_id="O3" value="3983" spread="41.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Ticagrelor on Day 7(2)</title>
        <description>The pharmacokinetics parameters of ticagrelor on Day 7---tmax</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Ticagrelor on Day 7(2)</title>
          <description>The pharmacokinetics parameters of ticagrelor on Day 7---tmax</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="37.09" lower_limit="1.00" upper_limit="3.03"/>
                    <measurement group_id="O2" value="2.00" spread="33.64" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.00" spread="43.00" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(1)</title>
        <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1---Cmax</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(1)</title>
          <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1---Cmax</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.28" spread="24.58"/>
                    <measurement group_id="O2" value="77.11" spread="53.92"/>
                    <measurement group_id="O3" value="138.6" spread="38.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(3)</title>
        <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1: tmax and t1/2</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(3)</title>
          <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1: tmax and t1/2</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="38.02" lower_limit="2.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="3.00" spread="34.14" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="3.00" spread="37.39" lower_limit="2.00" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t½</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.16" spread="51.42" lower_limit="8.22" upper_limit="17.1"/>
                    <measurement group_id="O2" value="11.64" spread="32.46" lower_limit="8.00" upper_limit="20.0"/>
                    <measurement group_id="O3" value="11.29" spread="53.84" lower_limit="8.74" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(1)</title>
        <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---Cmax</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(1)</title>
          <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---Cmax</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.7" spread="26.32"/>
                    <measurement group_id="O2" value="180.1" spread="49.83"/>
                    <measurement group_id="O3" value="300.6" spread="31.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(4)</title>
        <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 7---tmax</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(4)</title>
          <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 7---tmax</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="38.02" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2.00" spread="34.14" lower_limit="2.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.54" spread="37.39" lower_limit="2.00" upper_limit="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite : Parent on Day 1--Cmax</title>
        <description>To determine Cmax ratio for the metabolite to that of the parent compound on Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite : Parent on Day 1--Cmax</title>
          <description>To determine Cmax ratio for the metabolite to that of the parent compound on Day 1</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2277" spread="0.08984" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="0.2146" spread="0.06333" lower_limit="2.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="0.2005" spread="0.08334" lower_limit="2.00" upper_limit="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite : Parent on Day 7---Cmax</title>
        <description>To determine Cmax ratio of metabolite to that of the parent compound on Day 7</description>
        <time_frame>Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite : Parent on Day 7---Cmax</title>
          <description>To determine Cmax ratio of metabolite to that of the parent compound on Day 7</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2657" spread="0.07820" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="0.3082" spread="0.1223" lower_limit="2.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="0.2646" spread="0.06758" lower_limit="2.00" upper_limit="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Physical Examination, Summary of Abnormalities</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Physical examination</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Physical Examination, Summary of Abnormalities</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Physical examination</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="7.6"/>
                    <measurement group_id="O2" value="3" spread="9.7"/>
                    <measurement group_id="O3" value="2" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="9.0"/>
                    <measurement group_id="O2" value="0" spread="9.6"/>
                    <measurement group_id="O3" value="0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="16.0"/>
                    <measurement group_id="O2" value="0" spread="17.3"/>
                    <measurement group_id="O3" value="0" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head and neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal / Extremities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Hematology Laboratory Variables Over Time---hematocrit</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---hematocrit</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Hematology Laboratory Variables Over Time---hematocrit</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---hematocrit</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4083" spread="0.0365"/>
                    <measurement group_id="O2" value="0.4020" spread="0.0465"/>
                    <measurement group_id="O3" value="0.4153" spread="0.0369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---All Allowed Concomitant Medications During Study Treatment</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Concomitant medications</description>
        <time_frame>All allowed concomitant medications during study treatment(up to 2-5 days after last dose), includes medications that began prior to randomization but were ongoing after randomization.</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---All Allowed Concomitant Medications During Study Treatment</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Concomitant medications</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with allowed concomitant med</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="3.65"/>
                    <measurement group_id="O2" value="12" spread="1.86"/>
                    <measurement group_id="O3" value="12" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HMG CoA reductase inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="0.297"/>
                    <measurement group_id="O2" value="12" spread="0.186"/>
                    <measurement group_id="O3" value="12" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATORVASTATIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="0.200"/>
                    <measurement group_id="O2" value="8" spread="0.134"/>
                    <measurement group_id="O3" value="5" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIMVASTATIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.301"/>
                    <measurement group_id="O2" value="4" spread="0.111"/>
                    <measurement group_id="O3" value="3" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROSUVASTATIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="12.25"/>
                    <measurement group_id="O2" value="0" spread="17.89"/>
                    <measurement group_id="O3" value="4" spread="13.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta blocking agents, selective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="4.36"/>
                    <measurement group_id="O2" value="10" spread="5.91"/>
                    <measurement group_id="O3" value="6" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>METOPROLOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="1.5"/>
                    <measurement group_id="O2" value="6" spread="1.4"/>
                    <measurement group_id="O3" value="5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BISOPROLOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.36"/>
                    <measurement group_id="O2" value="5" spread="0.33"/>
                    <measurement group_id="O3" value="1" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACE inhibitors, plain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1.6"/>
                    <measurement group_id="O2" value="2" spread="2.0"/>
                    <measurement group_id="O3" value="6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PERINDOPRIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FOSINOPRIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ENALAPRIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BENAZEPRIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMIDAPRIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydropyridine derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AMLODIPINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NIFEDIPINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other cardiac preparations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRIMETAZIDINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRIMETAZIDINE HYDROCHLORIDE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biguanides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>METFORMIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>METFORMIN HYDROCHLORIDE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Organic nitrates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISOSORBIDE MONONITRATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin II antagonists, plain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IRBESARTAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOSARTAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TELMISARTAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alpha glucosidase inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACARBOSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulins and analogues for injection, fast-acting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INSULIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INSULIN HUMAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enzymes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KALLIDINOGENASE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Folic acid and derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FOLIC ACID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alpha and beta blocking agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CARVEDILOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other therapeutic products</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHINESE TRADITIONAL MEDICINE NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HERBAL NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preparations inhibiting uric acid production</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALLOPURINOL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfonamides, urea derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLIMEPIRIDE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLIQUIDONE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTIHYPERTENSIVES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTIHYPERTENSIVES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldose reductase inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPALRESTAT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin II antagonists and diuretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HYDROCHLOROTHIAZIDE+ LOSARTAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antidepressants in combination with psycholeptics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLUPENTIXOL+MELITRACEN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benzodiazepine derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESTAZOLAM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benzothiazepine derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DILTIAZEM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comb/complexes aluminium, calcium, magnesium comps</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HYDROTALCITE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FENOFIBRATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulins and analogues for inj,intermediate-acting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUMULIN 70/30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulins/analogues for inj,int/long-act+fast-actin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INSULIN ASPART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nicotinic acid and derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACIPIMOX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other antifungals for topical use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TERBINAFINE HYDROCHLORIDE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other drugs for peptic ulcer and GORD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GEFARNATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other vasodilators used in cardiac diseases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NICORANDIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thiazolidinediones</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROSIGLITAZONE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Causally Related Adverse Events by System Organ Class and Preferred Term</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Assessment of adverse events</description>
        <time_frame>Includes adverse events with an onset date on or after the date of first dose and up to and including the last study visit (up to 2-5 days after last dose).</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Causally Related Adverse Events by System Organ Class and Preferred Term</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Assessment of adverse events</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with any causally related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="3.65"/>
                    <measurement group_id="O2" value="2" spread="1.86"/>
                    <measurement group_id="O3" value="2" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.297"/>
                    <measurement group_id="O2" value="2" spread="0.186"/>
                    <measurement group_id="O3" value="2" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.200"/>
                    <measurement group_id="O2" value="2" spread="0.134"/>
                    <measurement group_id="O3" value="1" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.301"/>
                    <measurement group_id="O2" value="0" spread="0.111"/>
                    <measurement group_id="O3" value="1" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="12.25"/>
                    <measurement group_id="O2" value="0" spread="17.89"/>
                    <measurement group_id="O3" value="0" spread="13.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="4.36"/>
                    <measurement group_id="O2" value="0" spread="5.91"/>
                    <measurement group_id="O3" value="0" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.5"/>
                    <measurement group_id="O2" value="0" spread="1.4"/>
                    <measurement group_id="O3" value="0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.36"/>
                    <measurement group_id="O2" value="0" spread="0.33"/>
                    <measurement group_id="O3" value="0" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Ticagrelor on Day 1(1)</title>
        <description>The pharmacokinetics parameters of Ticagrelor on Day 1---Cmax</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Ticagrelor on Day 1(1)</title>
          <description>The pharmacokinetics parameters of Ticagrelor on Day 1---Cmax</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464.0" spread="38.02"/>
                    <measurement group_id="O2" value="413.9" spread="34.14"/>
                    <measurement group_id="O3" value="822.1" spread="37.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Ticagrelor on Day 7(3)</title>
        <description>Pharmacokinetics parameters of Ticagrelor on Day 7---AUC(0-12h)</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Ticagrelor on Day 7(3)</title>
          <description>Pharmacokinetics parameters of Ticagrelor on Day 7---AUC(0-12h)</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3882" spread="41.67"/>
                    <measurement group_id="O2" value="4351" spread="36.74"/>
                    <measurement group_id="O3" value="8206" spread="50.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Ticagrelor on Day 7(4)</title>
        <description>Pharmacokinetics parameters of Ticagrelor on Day 7---Accumulation ratio(ratio of Day 7 AUC(0-12h) to Day 1 AUC(0-12h))</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Ticagrelor on Day 7(4)</title>
          <description>Pharmacokinetics parameters of Ticagrelor on Day 7---Accumulation ratio(ratio of Day 7 AUC(0-12h) to Day 1 AUC(0-12h))</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.837" spread="23.57"/>
                    <measurement group_id="O2" value="1.882" spread="20.72"/>
                    <measurement group_id="O3" value="2.060" spread="22.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Vital Signs Over Time---Height</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Height)</description>
        <time_frame>Baseline</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Vital Signs Over Time---Height</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Height)</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.9" spread="7.6"/>
                    <measurement group_id="O2" value="168.8" spread="8.0"/>
                    <measurement group_id="O3" value="166.5" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Vital Signs Over Time---Weight</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Weight)</description>
        <time_frame>Baseline</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Vital Signs Over Time---Weight</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Weight)</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="10.2"/>
                    <measurement group_id="O2" value="73.8" spread="8.5"/>
                    <measurement group_id="O3" value="73.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Vital Signs Over Time---Pulse Rate</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Pulse Rate)</description>
        <time_frame>Baseline, Day 1 to Day 7 and 2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Vital Signs Over Time---Pulse Rate</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Vital signs (Pulse Rate)</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>BEATS/MIN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse Rate (BEATS/MIN)- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="8.6"/>
                    <measurement group_id="O2" value="60.5" spread="6.8"/>
                    <measurement group_id="O3" value="59.1" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate (BEATS/MIN)- Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" spread="8.4"/>
                    <measurement group_id="O2" value="60.6" spread="6.5"/>
                    <measurement group_id="O3" value="61.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate (BEATS/MIN)- Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="10.6"/>
                    <measurement group_id="O2" value="59.8" spread="7.3"/>
                    <measurement group_id="O3" value="63.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate (BEATS/MIN)- Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="9.8"/>
                    <measurement group_id="O2" value="60.4" spread="7.1"/>
                    <measurement group_id="O3" value="61.3" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate (BEATS/MIN)- Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="9.2"/>
                    <measurement group_id="O2" value="61.7" spread="5.5"/>
                    <measurement group_id="O3" value="63.7" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate (BEATS/MIN)- Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" spread="8.5"/>
                    <measurement group_id="O2" value="62.7" spread="7.1"/>
                    <measurement group_id="O3" value="64.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate (BEATS/MIN)- Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="8.5"/>
                    <measurement group_id="O2" value="59.9" spread="7.2"/>
                    <measurement group_id="O3" value="64.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate (BEATS/MIN)- Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="6.2"/>
                    <measurement group_id="O2" value="62.7" spread="7.8"/>
                    <measurement group_id="O3" value="62.9" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate(BEATS/MIN)- 2 to 5 days after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="10.9"/>
                    <measurement group_id="O2" value="61.8" spread="5.5"/>
                    <measurement group_id="O3" value="63.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(2)</title>
        <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1---AUC(0-12h), AUC(0-t) and AUC(0-inf)</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 36, and 48 hours post dose on Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(2)</title>
          <description>Pharmacokinetics parameters of AR-C124910XX (active metabolite) on Day 1---AUC(0-12h), AUC(0-t) and AUC(0-inf)</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="921.5" spread="28.66"/>
                    <measurement group_id="O2" value="1108" spread="34.83"/>
                    <measurement group_id="O3" value="1644" spread="30.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839.6" spread="25.23"/>
                    <measurement group_id="O2" value="906.0" spread="56.84"/>
                    <measurement group_id="O3" value="1534" spread="28.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464.0" spread="19.11"/>
                    <measurement group_id="O2" value="504.1" spread="55.41"/>
                    <measurement group_id="O3" value="835.9" spread="29.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(2)</title>
        <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---AUC(0-12h)</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(2)</title>
          <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---AUC(0-12h)</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1069" spread="24.89"/>
                    <measurement group_id="O2" value="1314" spread="41.02"/>
                    <measurement group_id="O3" value="2254" spread="37.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(3)</title>
        <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---Accumulation ratio(ratio of Day 7 AUC(0-12h) to Day 1 AUC(0-12h))</description>
        <time_frame>Plasma concentration was measured at Pre-dose, 0.5, 1, 2, 3, 6 and 12 hours post dose on Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(3)</title>
          <description>Pharmacokinetics parameters of Metabolite (AR-C124910XX) on Day 7---Accumulation ratio(ratio of Day 7 AUC(0-12h) to Day 1 AUC(0-12h))</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.304" spread="24.70"/>
                    <measurement group_id="O2" value="2.606" spread="28.34"/>
                    <measurement group_id="O3" value="2.697" spread="27.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Hematology Laboratory Variables Over Time---Erythrocytes</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Erythrocytes</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Hematology Laboratory Variables Over Time---Erythrocytes</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Erythrocytes</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>10^12/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.417" spread="0.319"/>
                    <measurement group_id="O2" value="4.409" spread="0.400"/>
                    <measurement group_id="O3" value="4.487" spread="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Hematology Laboratory Variables Over Time---Hemoglobin</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Hemoglobin</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Hematology Laboratory Variables Over Time---Hemoglobin</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Hemoglobin</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.3" spread="11.6"/>
                    <measurement group_id="O2" value="135.4" spread="15.2"/>
                    <measurement group_id="O3" value="138.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Hematology Laboratory Variables Over Time---Leukocytes</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Leukocytes</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Hematology Laboratory Variables Over Time---Leukocytes</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Leukocytes</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="1.23"/>
                    <measurement group_id="O2" value="6.30" spread="1.12"/>
                    <measurement group_id="O3" value="6.74" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Hematology Laboratory Variables Over Time---Platelets</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Platelets</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Hematology Laboratory Variables Over Time---Platelets</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Haematology---Platelets</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.3" spread="34.5"/>
                    <measurement group_id="O2" value="186.7" spread="38.5"/>
                    <measurement group_id="O3" value="227.3" spread="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Glucose</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Glucose</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Glucose</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Glucose</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" spread="3.65"/>
                    <measurement group_id="O2" value="7.26" spread="1.86"/>
                    <measurement group_id="O3" value="5.78" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Alanine Aminotransferase</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Alanine Aminotransferase</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Alanine Aminotransferase</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Alanine Aminotransferase</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>ukat/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.524" spread="0.297"/>
                    <measurement group_id="O2" value="0.429" spread="0.186"/>
                    <measurement group_id="O3" value="0.465" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Aspartate Aminotransferase</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Aspartate Aminotransferase</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Aspartate Aminotransferase</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Aspartate Aminotransferase</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>ukat/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.497" spread="0.200"/>
                    <measurement group_id="O2" value="0.410" spread="0.134"/>
                    <measurement group_id="O3" value="0.433" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Alkaline Phosphatase</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Alkaline Phosphatase</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Alkaline Phosphatase</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Alkaline Phosphatase</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>ukat/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.172" spread="0.301"/>
                    <measurement group_id="O2" value="1.027" spread="0.111"/>
                    <measurement group_id="O3" value="1.028" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Creatinine</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Creatinine</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Creatinine</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Creatinine</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.92" spread="12.25"/>
                    <measurement group_id="O2" value="87.50" spread="17.89"/>
                    <measurement group_id="O3" value="83.50" spread="13.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Total Bilirubin</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Total Bilirubin</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Total Bilirubin</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Total Bilirubin</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.98" spread="4.36"/>
                    <measurement group_id="O2" value="14.58" spread="5.91"/>
                    <measurement group_id="O3" value="14.81" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Sodium</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Sodium</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Sodium</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Sodium</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.7" spread="1.5"/>
                    <measurement group_id="O2" value="140.8" spread="1.4"/>
                    <measurement group_id="O3" value="141.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Potassium</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Potassium</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Potassium</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Potassium</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="0.36"/>
                    <measurement group_id="O2" value="4.47" spread="0.33"/>
                    <measurement group_id="O3" value="4.26" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Chloride</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Chloride</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Chloride</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Chloride</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.2" spread="1.6"/>
                    <measurement group_id="O2" value="103.9" spread="2.0"/>
                    <measurement group_id="O3" value="104.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Phosphate</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Phosphate</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Phosphate</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Phosphate</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.188" spread="0.183"/>
                    <measurement group_id="O2" value="1.154" spread="0.158"/>
                    <measurement group_id="O3" value="1.145" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Albumin</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Albumin</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Albumin</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Albumin</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.77" spread="1.51"/>
                    <measurement group_id="O2" value="44.68" spread="2.54"/>
                    <measurement group_id="O3" value="46.07" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Protein</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Protein</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Protein</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Protein</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" spread="3.6"/>
                    <measurement group_id="O2" value="69.8" spread="3.0"/>
                    <measurement group_id="O3" value="70.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Blood Urea Nitrogen</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Blood Urea Nitrogen</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Blood Urea Nitrogen</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Blood Urea Nitrogen</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.875" spread="1.500"/>
                    <measurement group_id="O2" value="6.392" spread="1.648"/>
                    <measurement group_id="O3" value="6.108" spread="1.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety---Clinical Chemistry Variables Over Time---Bicarbonate</title>
        <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Bicarbonate</description>
        <time_frame>2 to 5 days after last dose</time_frame>
        <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety---Clinical Chemistry Variables Over Time---Bicarbonate</title>
          <description>The safety of ticagrelor in Chinese patients with stable coronary heart disease on chronic low dose ASA.
Safety will be assessed by:
• Clinical Chemistry---Bicarbonate</description>
          <population>All patients who receive at least one administration of the investigational product and for whom any post-dose data are available will be included in the safety analysis set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.92" spread="2.77"/>
                    <measurement group_id="O2" value="28.55" spread="1.95"/>
                    <measurement group_id="O3" value="28.15" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite : Parent on Day 1--AUC(0-inf)</title>
        <description>To determine AUC(0-inf) ratio for the metabolite to that of the parent compound on Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite : Parent on Day 1--AUC(0-inf)</title>
          <description>To determine AUC(0-inf) ratio for the metabolite to that of the parent compound on Day 1</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3310" spread="0.09838"/>
                    <measurement group_id="O2" value="0.3403" spread="0.07381"/>
                    <measurement group_id="O3" value="0.3106" spread="0.1283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters of Metabolite : Parent on Day 7---AUC(0-12h)</title>
        <description>To determine AUC(0-12h) ratio of metabolite to that of the parent compound on Day 7.</description>
        <time_frame>Day 7</time_frame>
        <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 45mg</title>
            <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 60mg</title>
            <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 90mg</title>
            <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters of Metabolite : Parent on Day 7---AUC(0-12h)</title>
          <description>To determine AUC(0-12h) ratio of metabolite to that of the parent compound on Day 7.</description>
          <population>All randomized patients who received at least one dose of investigational product with post-dose PK measurements available and no protocol deviation considered to significantly affect PK of ticagrelor and its metabolite, AR C124910XX, will be included in the PK analysis set.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3132" spread="0.08899"/>
                    <measurement group_id="O2" value="0.3549" spread="0.1351"/>
                    <measurement group_id="O3" value="0.3153" spread="0.1120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor 45mg</title>
          <description>A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor 60mg</title>
          <description>A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.</description>
        </group>
        <group group_id="E3">
          <title>Ticagrelor 90mg</title>
          <description>A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST-T change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution and Principal Investigator may use the Study results (data generated at the site) and shall not publish or present any such results until the earlier of (i) the date of the first Study results publication and (ii) the end of the eighteen (18) month period following the completion, or early termination, of the Study at all participating sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rong Fu</name_or_title>
      <organization>Pharmaceutical Product Development, LLC.</organization>
      <phone>86-021-80135112</phone>
      <email>rong.fu@ppdi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

